151094-81-4

Basic information

• Product Name: (2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid
• Synonyms: (2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid;(2S)-2-(2,4-Dioxo-1,2,3,4-tetrahydroquinazolin-3-yl)-3-phenylpropanoic acid
• CAS NO: 151094-81-4
• Molecular Formula: C17H14N2O4
• Molecular Weight: 310.30406
• Mol File: 151094-81-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid(151094-81-4)
• EPA Substance Registry System: (2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid(151094-81-4)

Safety Data

• Hazardous Substances Data: 151094-81-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid is used as a potential pharmaceutical candidate for various applications due to its unique structure and chiral nature. Its potential biological activities, such as anti-inflammatory, antibacterial, or antifungal properties, make it a promising compound for the development of new drugs and therapies.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2S)-2-(2,4-dioxo-1H-quinazolin-3-yl)-3-phenyl-propanoic acid serves as a valuable compound for further study and development. Its structure and potential biological activities provide a foundation for exploring its interactions with biological targets and understanding its mechanisms of action. This knowledge can contribute to the design and synthesis of more effective and targeted pharmaceutical agents.

Upstream product

• 1793-07-3 methyl 2-isocyanatobenzoate 
• 63-91-2 L-phenylalanine 
• 41470-93-3 2-((ethoxycarbonyl)amino)benzoic acid 
• 3081-24-1 H-Phe-OEt 
• 134-20-3 2-carbomethoxyaniline 
• 4376-18-5 Monomethyl phthalate 

Relevant articles and documents

A general and efficient solid phase synthesis of quinazoline-2,4-diones

An efficient solid phase synthesis of chiral quinazolinediones is described. Immobilized amino acid based urea derivatives 3 undergo a racemization-free heterocyclization upon gentle healing in presence of tetramethylguanidine to afford fused pyrimidine-2,4-diones 6, which are smoothly N1-alkylated under mild conditions to produce immobilized quinazolinediones 8. The method is amenable to combinatorial synthesis and offers broad scope for structural and chemical diversity, as illustrated by preparation of fused thieno[2,3-d]pyrimidine-2,4-dione 10 and hydroxamate pharmacophore bearing quinazolinedione derivative 11.

Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones

The invention provides chemistry libraries containing fused 2,4-pyrimidinediones. The invention also provides methods for the construction of fused 2,4-pyrimidinedione containing libraries. The invention further provides methods for the identification of bioactive, fused 2,4-pyrimidinediones from those libraries.

Solid phase synthesis of chiral 3-substituted quinazoline-2,4-diones

The synthesis of chiral 3-substituted quinazoline-2,4-diones was performed starting from N-urethane anthranilamides. This synthetic pathway was applied in solid phase, from commercially available anthranilic acid that was bound to hydroxymethyl polystyrene resin via a carbamate linker. In both cases, cyclisation occurred under basic conditions to afford non-racemized quinazolinediones in high purity.

SYNTHESIS OF CHIRAL 3-SUBSTITUTED 2,4-(1H,3H)-QUINAZOLINEDIONES

2-Carbomethoxyphenyl isocyanate and 6-nitro-2-carbomethoxyphenyl isocyanate were generated in situ from half-esters and then converted into the corresponding quainazolinediones using α-amino acids.This useful annelation process was found to be a general m